18F-FLUDEOXYGLUCOSE (18F-FDG) SOLUTION Canada - English - Health Canada

18f-fludeoxyglucose (18f-fdg) solution

isologic innovative radiopharmaceuticals ltd. - fludeoxyglucose 18f - solution - 7400mbq - fludeoxyglucose 18f 7400mbq - roentgenography

SODIUM ACETATE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium acetate injection, solution, concentrate

woodward pharma services llc - sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium acetate injection, usp is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp is contraindicated in patients with hypernatremia or fluid retention.

CARBOPROST TROMETHAMINE injection, solution United States - English - NLM (National Library of Medicine)

carboprost tromethamine injection, solution

woodward pharma services llc - carboprost tromethamine (unii: u4526f86fj) (carboprost - unii:7b5032xt6o) - carboprost tromethamine, usp is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: - failure of expulsion of the fetus during the course of treatment by another method; - premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; - requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; - inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intr

SELENIOUS ACID injection, solution United States - English - NLM (National Library of Medicine)

selenious acid injection, solution

woodward pharma services llc - selenium (unii: h6241uj22b) (selenium - unii:h6241uj22b) - selenium injection is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (tpn). administration of selenium in tpn solutions helps to maintain plasma selenium levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. selenium injection should not be given undiluted by direct injection into a peripheral vein because of the potential for infusion phlebitis.

TEVA-TERBINAFINE TABLET Canada - English - Health Canada

teva-terbinafine tablet

teva canada limited - terbinafine (terbinafine hydrochloride) - tablet - 125mg - terbinafine (terbinafine hydrochloride) 125mg - allylamines

TEVA-TERBINAFINE TABLET Canada - English - Health Canada

teva-terbinafine tablet

teva canada limited - terbinafine (terbinafine hydrochloride) - tablet - 250mg - terbinafine (terbinafine hydrochloride) 250mg - allylamines

AURO-TERBINAFINE TABLET Canada - English - Health Canada

auro-terbinafine tablet

auro pharma inc - terbinafine (terbinafine hydrochloride) - tablet - 250mg - terbinafine (terbinafine hydrochloride) 250mg - allylamines

TRIFERIC AVNU- ferric pyrophosphate citrate solution United States - English - NLM (National Library of Medicine)

triferic avnu- ferric pyrophosphate citrate solution

rockwell medical inc. - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - triferic avnu is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). limitations of use - triferic avnu is not intended for use in patients receiving peritoneal dialysis. - triferic avnu  has not been studied in patients receiving home hemodialysis. none risk summary there are no available data on triferic avnu usein pregnant women to inform a drug-associated risk of major birth defects,  miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, intravenous administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes at maternally toxic dose levels that were higher than the maximum theoretical amount of iron transferred to patients from triferic avnu (see data) .  the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregna

TRIFERIC AVNU SOLUTION Canada - English - Health Canada

triferic avnu solution

rockwell medical inc - iron (ferric pyrophosphate citrate) - solution - 1.5mg - iron (ferric pyrophosphate citrate) 1.5mg - iron preparations

PYRIDOSTIGMINE BROMIDE solution United States - English - NLM (National Library of Medicine)

pyridostigmine bromide solution

woodward pharma services llc - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.